Distinguished in Neuroendocrine Tumor

Ana B. Custodio

El Pardo, MD, ES 
Distinguished in Neuroendocrine Tumor
El Pardo, MD, ES 
OverviewLocationsClinical Research

Overview

Ana Custodio practices in El Pardo, Spain. Ms. Custodio is rated as a Distinguished expert by MediFind in the treatment of Neuroendocrine Tumor. Her top areas of expertise are Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, Stomach Cancer, and Colorectal Cancer.

Her clinical research consists of co-authoring 69 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles and participated in 2 clinical trials in the study of Neuroendocrine Tumor.

Gender
Female

Locations

El Pardo, MD 28046, Spain
Other Locations
La Paz, MD, Spain
La Paz, CN, Spain
Madrid, MD 28029, Spain
Castellana, MD 28046, Spain
Murcia, MU, Spain
Majadahonda, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients with GEP-NET
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients with GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2024
Intervention Type: Drug
Study Drugs: CAM2029, Octreotide LAR, Lanreotide ATG
Study Phase: Phase 3
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Unknown
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

69 Total Publications

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger.
DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger.
Journal: Frontiers in pharmacology
Published: June 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Custodio's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile